OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2026-03-31-accounts

MOORE THOMPSON INFLAMMATORY NEUROPATHIES UK (fomierly Gullllan-Barre & Associated Inflammatory Neuropathles (GAIN) CHARITY COMMISSION REGISTERED NO: 1154843 & SC039900 STATEMENT OF ACCOUNTS for the year ended 31st March 2026

INFLAMMATORY NEUROPATHIES UK Contents Page for the year ended 31st March 2026 INDEX Legal and Administfalr¥e InforMa￿n Truslee5' Annual Rep)rt Independent Examirnf s Repjrt Statement of Financial Actmties Statement of Financial PosI￿n 10 Notes lo the Accwnts 11-22

INFLAMMATORY NEUROPATHIES UK Legal and Adminlstrative Information for the year ended 31st March 2026 Trusteos Carol Hooper- Chair Sean Austin - Treasurer Jenny Willison (resigned 4 October 20251 Lee Raynor Iresigned 4 October 20251 Jatinder Paul James Wilson Stephanie Parker Lora Barelay Derren Sanders lappoinled 16 October 20251 Prn81dtnt Emerltus Glennys Sanders MBE Patron• Air Marshal Sir lan Maclayden KCVO CB OBE FRASS RAF Rld Professor Richard Hughes MD FRCP Fmedsci Chlèf ExoGUtlve Offlcer Rich Collin8 Reglstered Offlco 3 Mill House Carre Street Sleaford Lincolnshire NG34 7TW Indepèndent Examlner H J Bri9ht BA, FCA. CTA M¢)ore Thompson Limrted Bank House Broad Street Spalding Lincolnshire PE11 1TB Bankers CAF Bank 25 King's Hill Avenue West Malling ME194JQ Page 1

INFLAMMATORY NEUROPATHIES UK Trustees. Annual Report for the year ended 31st March 2026 The Injslees of Infflammalory Neuropaths UK present th￿[ annual report for the year ended 31 Mareh 2026 under the charit￿S Act 2011. The report has been prepared in accordance wrth Inflammalory Neuropathies UK'S governing dttumenl and the Statement of ReC￿nrnended Practti (SORP FRS 1021 Financial Reporting Standard appI￿ab￿ in the UK and the Republ￿ of Ireland. Our legal slalus and governance structure are explained in Ihe'struclure, govemance and management, section of this report. The Charity operated under the name GuilLgin-Barré and Assctiated Inftammalory Neuropaths (GAINI until 1st May 2025, when the name changed lo Infiammatory Neuropathie5 UK. ObJ•¢llv•8 and Actlvh iv Inflammatory Neurcpaths UK is the onty UK chaity ￿ttl¢h ffj ccffnp￿tsty ￿ed￿ated lo supporting people impxted by GUil￿1n-Barlè SyndrcAne IGBSI, CIDP, MMN, and other Infiammatory Neuropathies. We offer support lincluding eMOt￿nal supForti. personal grants, local groups, online fowm$, and much more. We provNJe support ab)ng$￿e a community of peop￿ wrth lived &xpenence, supporting people lo help each other. We false furKls for reseafch and even carry out some soekql research oursefves. We work right across the UK, also providing support lo Feople in the Republ￿ of Ireland rf they ask for rt. We are here for people ¥￿ether they have one of these condth"on$ themselves, are Suppth'ng a fri￿￿ or a family member. or afe a medKal professional. We arg Infflammatory Neuropath￿ UK. and wg are IN this loJetlw. Thè Iruslees eonfim) thal they have referred lo the inf0mat￿n contained in thè Chafty Crynmi$$ion's general guidanee on publ￿ benefrt then revwng Ihe Charrty's aims and objectNes, and In planning actiwties and strategy for the year ahead. The aclTvils that we cary out to further tyjr Charrtab￿ purpose5 are for the public benefrt. Our objectives, as set out in our Constr(uiw. are lo relve the need$ of people impacted by Inflammalory Neuropathies. Ihwr families, and cafers in particular bul nol exclusivety by. 8. The provision of infomiatw. support. rw)n-medtsl advu. aThJ other assistance". b. The prcrfnotion of re50arch into the causes. prew11￿, and treatment of Infiammatory Neuropathies., and . Advancino the awareness of the publ￿ and of the med￿1 profess￿ft$ conceming InfI￿rnatory Neuropathies, their cau8e8. impacts, prewnlion, 8nd treatment. Achievemonts •nd wrfomi•n¢• 202512026 was another excel￿nI yaar for Inflammatory Neuro￿h￿ UK. We have continued to gT¢)w and develop. and to reach and support more people. This woukln'l have been ￿sIble wthoul our incredible staff, team. our amazing volunleefs, arKI our dedicated Board of Twsteas. rtin im drtp)ns. Peopbe are a￿y$ at the centre of evtyhing that Inflammatory Neufopalhes UK does, and that has been no sjifferent in 2025r26. Oui Inllammatory Neuropathies Communty ￿ad5 eve￿hing we do, and we have Gonlinued to engage with and listen lo peop￿ on a regular basis. to ensure our servw and our support are what people want and need. Foll¢Mng on from the sMJnrfKanl slrKles foTrvard we made kgsl year. we continue lo deveh)p our core offer, and add now opportun1th￿ to the rnenu of 8ervrs we provide and make available to our Gommunity. We hav¢ lurther ensured that suppcKt is our primary focus. and are c(x)linuousty improvin9 how we respond lo enquiries and offer support Our person-cenlred approach, rather than a service-led model continues to evofve. and we have add￿ In and emotional support Serv￿ in 2025. as well as further devek)ping inhouse provision, targeting support lo indiwdual needs on a bespoke basis. and rev￿￿n9 arKI broadening our key Se￿iceS SLbch as our Online and Lc￿1 Get Togethers. The key aim of thts eontinue(l improvement and devek)pment has been lo reach more Feople and to improve the SUPF#Jt they receNe fr(Mn us. Page 2

INFLAMMATORY NEUROPATHIES UK Trustees, Annual Report for the year ended 31st March 2026 hi9¥gments and perfomiancè continued As a result of these changes and our different approa¢he$, we have once again been able to 8UPPQrt an increased number of people. In 2025126 we directly supported 937 people, an increase of 57% from the previous year We also monitor the number of activities that we undertake In support of people. In 25126 this was 5,349, an increase of 630h. Of the 937 people supported, 48 received peer support from one of our incredible volunteers, and 25 pgople received a Personal Grant, an increase of 670A, with a total spend of £24.941. In addition to Ihesg figures, we received the Initial report from Rareminds with regard to our new Emotional Support Service up lo Ihe end of 2025. This saw an inrtial 9 pèople supported, through 62 Sessions of support, with 1000A highlighting positive outcomes. We were al80 ab￿ lo increase the number of peopLq supported through OUT onlin8 groups. wlh 138 people attending throughout the year. These groups continue lo be popular with regular attendees, pgople newly diagnosed, and those who want ad hoc connections and support when they need it. We added a new MMN group in February, providing an additional ¢ohort ol peopL* with this support. As athys, there was a significant demand for in pefson support, and our L¢xal Gel Tc>Jethers We￿ there to deliver it. We have been working hard wilh our volunteers and our communrty lo recruit fa¢ililalors and to grow the number of groups provided In 202S126 we launched a new Essex Gel Together, which has joined Lan¢ashire and Cumbria, and Yofkshire as regular groups. We held one off L¢cal Get Togelhers in Bimiingham and Edinburgh, bul these did not continue past their Initial meeting. As a re$ull. we did not hrt our grovAh target, bul have successfulty recruited more volunteers lo this role. and are on target to grow tho number of group$ in 26127. During tho year. our membership eonlinued lo grow. alkil al a 188ser rale than last year. In 25r26 ￿ ended th• year with 1,826 members, an increase of around 2.3% One of our biggest strategic aims is lo increase our reach and engagement. By reaching more people, we can support more people. We have strived lo do this In a number ol ways. Our social media presenee ha¥ grown signifieanlly wrth 15% more followers across all channels, a 310A increase in enga9emenl. and an average of 80.000 impressions on social media per month. Thi5 has been a great 8UCCèSS. Our website has al80 s¢on significant gr0￿h, particularty following the launch of the new website under the Inflammatory Neuropathies UK branding. The website saw 70,091 user last year, and an increase of around 57.50h. Our annual survey again demonstrated that the monthly newsletter was important lo people. We sent out 12 newsletters in 25126 to a steadily gr¢)wing number of Subscribers. On average this was ofound 1,950 people each month, and a total of over 23,000 people over the year. Newsletter emails are opened on average by 26.5% of people. meaning around 6.100 people were reached and inleraeted wrth ono of our new51etter5 in 25126. We continue lo improve our monitoring and reporting on impaci. ouleomès, and outputs. While there Is still some way lo go, we are now reporting monthly on a wider sel of impael measures, whrh allow u8 to better understand what we delivor. and how we can make improvements. We have further developed and improved our Imp&t Report, and continue lo undertake an annual survey of our community, lo best understand what people want and need, as well as what they expect from the Charrty. This and the metric$ from our performance are used to improv6 what we do on a constant basis. Trials and research As a charity. we always want lo support research. and in 2025126. we were able to fund Universty of Oxford £25,000 lo support a PhD student's research into antibody research. This year we also supported 2 clinieal liials, and around 5 rgsearch inrtiatives. We delwered a pl￿? of reSea￿h in collaboration with other organi5ations IhBt lod to two poster presentations with Innammatory Neuropath￿ UK branding. We a150 responded to over 10 natk)nal and international consultations. We worked with over 20 organisalions on collaboratwe approaches, campaigns, and development opportunrties. Page 3

INFLAMMATORY NEUROPATHIES UK Trustees. Annual Report for the year ended 31st March 2026 Achievements and p•rfornian¢• ¢ontinu8d Every year. wo undertake an annual survey with c￿r Community, as part of an active listening and engagement prtsJram. We undert￿k our survey In early 2026. in o¥der to better understand how we were performing, as well as finding out what people's expectat￿n$ were of us. Responses in 2026 were up on 2025. and we I￿10 ab￿ to gathèr some excellent infofmatKJn lo hèlp guide our work In the year ahead. Key takeaways were . People thoJghl we supwrted people VÈll. and commun￿led effectNety - Pecple thought we could improve our adve￿CY work. •wareness raising. and résearch - Pecple wanted better ￿5S to emol)nal and mental health Sup - Pecplo wanl¢d more epp)rtunrties to Connect wrth othe(s Over 25r26 we were abk to continue buikling on our awareness raisir@. marketing, and engagement. This locus has allowed us lo $￿n￿1¢an1ty increase our reach and engagement. %wth sockil media and the websrte being the focus ol this adNty. This was drwen from May ty our rebranding exefcise. wh￿h &iw US fename and rgbrand the or9anisatNJn The feedback ol thts exercise has been overythelmingly positNe. ￿th the new name being well rgceived, the new1090 and branding being much loved. and comments around a more profossKJnal and inclusive brand being much appreciated. Partnership and collaboration remain front and Cent￿ lor lh Charrty, wrth continued work wrth colleagues worthide, and xross the sector in the UK. These link5 have helped wrth our Influence and a(Ivocacy work, Supported our reach and our imp%t. and helped us lo better establish oursefves wrth both a national and glcl)al voice. We continue to build batter links wrth polw makers and decisv)n mokeis within thè various levels of UK Govemmenl, and beyond This has ￿ us lo meelings wrthin the Houses of Padiament and Lords. as well as in Holyrc¢)d. We continue to build Je - Improved Advocacy of our Communty P4e4

INFLAMMATORY NEUROPATHIES UK Trustees. Annual Report for the year ended 31st March 2026 Financial rèview a. Goin Concem After making appropriate enquiries. the Iruslees have a reasonab￿ expectation that the Charty ha5 adequate resources to continue in operational existence for the foreseeable future. For this rea50n, they continue lo adopt the going concern basis in preparing the financial stalemenls. Further details regarding the adoption of the going con¢ern basis can be found in the Accounting Polieie5. b. Our finances for our r 2025126 Our consolidated financial 518lemenls for the year are shown on pages 9 10 22. A summary of the financial results lor the year is sel out below. In min re Toial income for the year was £510,498 which showed a increa¥e of £314,386. Thi8 was due to a increase in legacy donations. This year has seen expenditure in¢rease from £203.288 10 £286,760 . This equates to an inerea$• of around 41.1Q/o. If we look al income as a whole. we can see that our strategy lo diversify our income has begun lo take effect. with grants and research income added in the year. Our position with regard lo donations and lundrai¥ing is faidy siable, with performancè actually increasing in some key areas. This is against the trends seen with the majonty of charities, and we aro delighted that the generosity of the public has bèen so posrtive in 25126. Even with our financi81 strategy in place. the unprediclabilily of income means that il remains difficult lo predlcl income and lo plan accordingly. However, as wrth last year, careful budgèt planning, management and monitoring by our Financial Sub-committe8 has delivered better financial performance than èxpected. Our policy is lo invest lunds In the ongoing expansion of our work, bul lo relain sufficient levels of available reseNes lo enable us to continue our core slralegi¢ activities in the event of a signrficanl downturn in our ineome. This considers risks associated with our income streams. our ongoing investment in delivering our strategies, the varying need$ of our members, longer term cash flow projections, and other relevant business We have identified sufficient levels of available reserves as being a minimum of 6 months of our planned expenditure. We reeognise Ihat there may be circumstances where reserve levels fall below this largel range. H¢)wever. if this was the case, there would be a clear action plan lo restore them. Our investment policy for these reserves is reviewed by the Board on an annual basi5, Our object￿e Is lo seek lo produce the best financial return wthin an acceptable level of nsk for the bulk of the assets, referred lo as the Yinancial investments,. Tho Investment portfolio is invested to direclty further the Charity's aims. The performance of our investments is kept under review. We keep our funds with UK-based institutions with a strong credit rating. and we keep our policy under review in the light of changes lo the financial climate The Board of Trustees has reviewed the Inflammatory Neuropathies UK financial position and believes the￿ are sufficient resources lo manage any operational or financial risks. As of 31 March 2026, our total funds to be Carried over were £1,243,06012025126'. £992,579). Of this amount. £1,278,90312025126.. £1,002.5211 represent5 the assets of the Charity, including the land and buiklin9 that wo own. Our policy is that we should have a minimum of 6 months, operating costs In reserve. This equales to approximately £169,000. We calculate free reserves lotaling £918,864 as of Mafch 202612025126.. £709,059). Structure, governanc• and management The Charity was founded in 1985 and rebranded as a CIO in 2014. The Charty 15 a Charitable Incorporated Organisation and is regulated by the Charity Commission in England and Wales- no 1154843 and the offi￿ of the Scottish Regulator- no SC039900. Our constiiution was updated following our name change in May 2025, and again wrth some minor change8 to update wording in October 2025. Page 5

INFLAMMATORY NEUROPATHIES UK Trustees, Annual Report for the year ended 31st March 2026 Structure. govemance and management contlnued Tr Our governing body, the Board of Trustees Ilhe Board), is responsible for the overall governance and work of the Our Iruslees are volunte8rs and do not receive any remuneration for their services, bul may Claim reasonable expenses incurred through attending meetings or other duties. The Board meels monlhty and is responsible for directing the affairs of the Charity, and ensuring that il is solvent, well run and delivers the charrtable outcomes for the benefrt of people impacted by GBS, CIDP, and related condrtions. Trustees who served during the year are listed on page 1. Trustees can be recruited from w((hin the membership or from Olrtside The Trustees are elected by the membership at the Annual Genoral Meeting. The full terms for Trustees can be found in our Constrtution. During the year Jenny Willison and Lee Raynor retired a$ Trustees having seNed their full terms. We woukl like lo thank Jenny and Lee lor their work with and support of the charity over their tenures. inin ru Potential Iruslees attend an interview lo assess their suilabilily for the role Al this inlgrv1ew they are also told about the r8sponsibililies of Trustees,. the Conslilulion and other documontalion., the linancial silualion., and existing strategy. Following interview, successful applicants meet the whole Board al the next avai18ble Board moeling as an observer.11 the Board is Satisfied and the applicant wishe$ to proceed, they will bg invited to loin and are co-opted until the next AGM at which lime they may sland for election. The Board deleg8les operalional planning and day-lcpday management of the Charity to the Chief Executive, supported by the Charity's 8tsff. Th￿ authority Is delegated within approved limits. Staffing lfrvels are foul full- time staff. We have a comprehensive nsk regi81er which considers plans and stralegias lor rniligaling risk. The register is reviewed throughout the year by the Chief Executive who updates the Board on tho slalus of the key risks and issues, as well as any mrtigalions. as part of the regular reporting lo each Board meeting. Tru8tee8' responslbllltles statement The Trustees are responsible for proparing the Trustees, Report and the financial slalemenls in accordance wrth applieable law and Unrted Kingd¢)m Accounting Stsndards (United Kingdom Generally Accepted Accounting Practice). The law appI￿able to ¢harilies in Englandlwales & Scotland reqLti￿S the Tw$loes lo prepare financial slalements for each financial year which give a true and lair view of the slate of affairs of the Charity and of the incoming resources and appliealion of resources of the Charity for that period. In prepaiing these financial Statements, the Trustees are required lo.. $8lècl suitable accounting policigs and then apply them consislenlty., observe the methods and principles In the Charrties SORP IFRS 102}", make the judgements and accounting eslimales Ihal are reasonable and prudent., prepare the financial statements on the going concern basis unkss (( is inappropriate to presume that the Charity will continue in operation. The Ifuslees are responsible for keeping adequate accounting records that are sufficient lo show and explain the Charitys tranaaGtions an(J di8clo8e with rea?onable aGcuracy at any time the financial po$ition ol the Charity an enable them to ensure that the financial statements comply with the Charrties Act 2011, the Charity (Accounts and Reports) Regulations 2008, the Charities and Trustee Investment (Scollandl Act 2005. the Charrties Accounts (Scollandl Re9ulalions 20(￿ las amended) and the provisions of the Memorandum of Association. They are 81s0 ￿SPOnSible tor safeguardin9 the assets of the Chanty and hence foi taking raasonable steps for the prevention and detection of fraud and other irregularities. This report was approved by the Trustees, on 3rd October 2026 an¢J is signed on their behalf by.. Carol Hooper, Chair Page 6

Independent Examinerfs Report to the Trustses of INFLAMMATORY NEUROPATHIES UK for the year ended 31st March 2026 l ￿port lo the charty Iruytees on my examination of the accounts of the charity for the year ended 31 March 2026 which are sel out on pages 9 to 22. R•sponsibilltles and bas5$ of roport As the Trustees of the Charity you are responsible for the preparation of the accounts in 8ccordan¢e with the requirements of the Charf(ies and Trustee Investment Iseollandl Act 2005 Ilhe 2005 Aet'l, the Charities Accounts (Scollandl Regulations 2006 las amended) I'lhe 20C6 Accounts Regulalions'l and the Charities Act 20111'lhe 2011 Ad'l. You are satisfied that your charrty is not required by charrty l&Y to be audited and h8ve chosen instead lo have 8n independent examination. I report in respect of my examination ol the Charitys accounts carried out under section 4411 Ilcl of the 2005 Act and seelion 145 01 the 2011 Act. In carrw'ng out my examination I have followed Ihe requirements of Regulation 11 of the 2006 Accounts Regulations and all applicable Directions given by the Charty Commission under section 145ISllbl of tho 2011 Aci. Indopendent oxamln•rf¥ ¥tatem8nt Since th8 Charity has prepared ils aeeounls on an accruals bas¢s and is regislor¢d in Scotland your examiner musl be a member of a body listed in Regulation 11121 of the 2006 Accounts Regulations. I can confirm that l am qualrfied lo undertake the examination because l am a regislereil member of Institute of Chartered Accounlanls in England and Wales. which is one of the listèd bodies. Your attention is drawn to the fact that Ihg Charity has prepared the accounts in accordance vAlh Accounting and Reportin9 by Charrties.. Statement of Recommended Practicè applicable to charil*s preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 in preference to the Accounting and Rèporting by Charrties.. Statement of Recommended Practice is$Ltgd on 1 April 2005 which is referred to in the extant regulations bul has been withdrawn. l understand that this h85 been done in order for the accounts lo provide a true and fair vow in accordance with the Generally Accèpted Accounting Practice effeetive for reporting periods beginning on or after 1 January 2015. I have ¢ompleled my examination. l ¢onfim that no material matters have come lo my attent￿n in conneelion wf(h the examination giving me cause to beI￿ve that in any material respect.. 1. accounting records were not kept in respect of the Charity as required by Section 4411llal of the 2005 Act, Regulation 4 of the 2006 Accounts Regulations, and section 130 of the 2011 Act.. or 2. the accounts do not accord with those iecord8', Of 3. the accounts do not comply wlh the accounting requiremonls of Regulation 8 of thè 20C6 Accounts Regulations and the applicable requirements Concerning the forrn and conlenl of accounts sel out in the Charities (Accounts and Reports1 Regulations 2008 other Ihan any requirement that the accounts give a 'lrue and fair, view which is not a matter considered as part of an inde￿ndent examination. I have no concerns and h8ve come across no other matters in connection wrth the 8xaminalion to which attention Should be drawn In this feport in order to enable a proper understanding of the aecounls lo be ached. Page 7

Independent Examinerfs Report to the Trustees of INFLAMMATORY NEUROPATHIES UK for the year ended 31st March 2026 This rewrt is made SOW to Chartys Trustees, as a trKJy, in xcordance with Part 4 of the Charrties (Accounts and Reports) Regulations 2(￿ and ReguL9t￿n 11 of the ChantEs Accounts {Sc()tlandl Regulations 2006. My wod( has been undertaken so thal I might stale to the Chartys Trustees those matters l am required to slate to them In an Independent Examine¢s Report and lor no other purpose. To the fullest extent pemiitted by law. I do not accepl or assume responsibility lo anY￿e other than the Charty and the Chantys Trustees as a bc4, for my or for this report. Heather Bnghl BA IHonsl, FCA. CTA Moore Thompson Limfted Chartered Accountants Spalding 08te'. Page 8

INFLAMMATORY NEUROPATHIES UK Statement of Financial Activities (Income and Exponditurn Aeeount for tho yoar èndèd 31st March 2026 Notes 2026 Unro$tricted funds 2025 Totsl Total Incomo from.. Donations and legacies Fundraising Other trading activities Investments 490,369 1,333 5,004 13,792 490,369 1.333 5,004 13,792 174,840 3.843 3.979 13.450 Total IncomSng rosourc•$ 510,498 510,498 196,112 Expgndlluro on: Raising funds Charitable activities 4.253 282.507 4,253 282.507 6,266 196,962 Total •xpend•d reBourc•• 286,760 286.760 203,228 Net Incom• boforo g•ln•lllos•os on Invè•tm•ntsl 223,738 223,738 17,116 Nel gains I Ilossesl on inve5tmenl$ Nel g8ins I Ilossesl on inve8lmenl propertie$ 5.093 21,650 5,093 21,650 4,906 Not mo¥om•nt In fund• 250,481 250.481 12,2101 Reconclllatlon of fund•: Total funds brought forward 14 992.579 992,579 994,789 Totsl funds carrfed fo￿ard 11 1,243.080 1,243,060 992,579 All income and expendilure derive from continuing a¢livili&s. The slalemenl of financial ath'vlb'es Includes all gains and losses recognised during the year. The notes on pag9s I 110 22 fomi part of Ihese lin8nci81 statements Page 9

INFLAMMATORY NEUROPATHIES UK Statement of Financial Positlon at 31st Ma￿h 2026 2026 2025 Totsl Total Flxèd ass•ts Tangible assets Investment propety Inve$tment$ 24,196 300,000 121,672 283.520 116.579 445.868 400,099 Current assets Debtors and prepayments Cash at bank and in hand 7.291 825,744 21.983 580.439 833.035 602.422 Cr•dltorn: Amounts falling due wfjthin one 135,843 {9,942} N•t ¢urr•nt a•s•t• 797,192 592,480 Totsl al￿14 l••• curr•nt Ilablllti 1,243,060 992,579 N•t A•••ts 1.243.060 992.579 Ch•rSty Fund• Unre$lricted 11 1,243.060 992,579 1.243.060 992,579 These finanaal stateff*nl$ vwe approved by the Trustees and are signed on their bettalf by" Carol Hooper Chair Date." 3rd O￿ober 2026 P8ges 1110 22 fonn part of these f￿anCIal statements Page 10

INFLAMMATORY NEUROPATHIES UK Notes to the Financial SLit•mènts for the year ended 31st March 2026 1. Genoral Infom)ation Inflammatory Neuropathies UK Is a Charitable Incorporated Organisalion Regislefed in England and Wales. The pnncipal office address is 3 Mill House, Carre Street, Sleaford. Lincolnshire. NG34 Trw. Accounting Policies 2.1 8asis of preparation of financial statomonts The financial slalemenls have been prepared in accordance wi(h the Charrties SORP IFRS 1021- Accounting and Reporting by Charities." Slalemenl of Recommended Pracliee applicable lo charrties preparing their a￿Ount$ in accordance wilh the Financial Reporting Standard applicable in the UK and Republic of Irojand IFRS 1021 (effective 1 January 20151, the Financial Reporting Standard appl+¢able in the UK and Republic of Ireland IFRS 1021 and the Charities A¢t 2011, the Charities and Trustee Investment IS¢ollandl Act 2005 and the Charities Accounts Iscollandl Regulations 2006 las amended). The financial ststemenls have been prepa￿￿ lo give a 'lrue and fair, view and have departed from the Charities (Aceounls and Reports) Regulations 2008 only lo the extent required lo provide a 'lrue and fairf view. This departure has involved following the Chanties SORP IFRS 1021 published on 16 July 2014 rather than the Accounting and Reporting by Charities.. Slalement of Recommended Practice affèctive from 1 April 2005 which has sin¢8 been ￿￿thdraWn. Thè financ￿1 slalements have been prepared under the historical cost convention wrth rtem recogni$ed at ost or transaction value unless otherwise slated in the re￿vant notes to these accounts. Tho financial ststemenls are prepared in sterling, which is the functional currency ol the Charrty. Monetary amounts in these financial ststemenls ale rounded lo the nearest £. Inflammatory Neuropathies UK meets the definition of a public benefit enlily under FRS 102. Assets and liabilrties are initially r¢¢ognised al hislori¢al ¢osl or transaction value unless othe￿iSe slated in the relèvant accounting policy. 2.2 Golng Con¢em After making appropriate enquiries. the Trust￿ have a reasonabl8 expectation that the Charity has adequale resources lo continue in operational existence for thè foreseeable future. The Trustees deemed that the Charity can meet ils commilmenls and liabilities and can continue for the foreseeable future. Accordingly, they ¢onlinue lo adopt the going concern basis in prèparing the fin8nci81 stalemenl$. 2.3 Incom& All income is reco9ni$gd once the Charity has gnlillement lo the income, f( is probablè that the incom& wll be received and the amount ol incomg receivable can be measured reliably. The recognrtion of income from legacies is dependent on establishing enlillemenl, the probabilty of receipt and the ability to g$1imale with suffieienl accuracy the amount receivable. Evidence of enlrtlement lo a legacy exists when the Charrty has sufficient evidence that a gift has been left lo them (through knO¥￿edge of the exislenco of a valid will and the death of the benefaclorl and the executor is salisfiad that the property in question will not be required lo satisfy claims in the estste. Receipt of a legacy musl be recognised when rt Is probable that it will be received and the fair value of the amount receivablè, which will generally be the expeeted cash amount to be distributed lo the Charity. can be reliably measured. Income from trading 8Ctivrties and fundraising is received in exchange for Supplying goods and services in order lo r8ise funds and is recc>Jnised when enlrtlemenl has occurr&J. Income tax recoverable in relalion lo donations received under Gift Aid or deeds of covenant is recognised al the lime of the donation. Income tsx recoverable in relalKJn to investment income is recognised al the lime the investment InGome 15 receivable. Inleresl on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity.. this is nomially upon notrfication of the interest paid Of payable by the institution with whom the funds are deposited. Page11

INFLAMMATORY NEUROPATHIES UK Notes to the Financial Statements (continued) for the year ended 31st March 2026 Accounting policies Icontinuedl 2.4 Expenditure Expendrture is rec(Jntsed once tlwe is a legal or constructi4E Obl3at￿Tr lo transfer economic benefit to a third paty. it is probable that a transfer of economic benefrts will be required in Sett￿ment and the amount of the 0b1NJ8t￿n can be measured rdiabty. Expendrture is classrf￿d by actsvty. The costs of each actNity are made up of the total of direct costs and shared costs. i￿luding support costs Invo￿ed in undertaking each aclNity. Direct costs artr￿lrtab1e to a single actNrty are al(tsled directty to that activity. Shared costs which contribute lo MO￿ than one actmty and suppcKt costs which are not attributable to a single aclmty are apportioned bthn those activrties on a basis consistent wrth the use of resources. Central staff costs are allo¢oted on the basts of lime spent. and depreciatK)n charges althaled on the pO￿.0n of the asset's use. Expenditufe on raising funds includes all expenditu￿ incurreil by the Charrty lo raise funds for rts charrtable purposes and includes costs of all fundraising actMtEs events and non<hantable trading. Expenditure on Charrtab￿ actNf(ies Is incurred on dÈrectty undertaking the activrties whrh further the Charty5 objectives. as well as any associated support costs. Grants payable are charged in the year when the offer is made except in those c2ses where the offer is conditional, such grants being recognised as expendrture when the condf(ions attachirg are fU￿lISed Grants offered subject lo condrtions haNE not been met at the year eThJ are noted as a commitment, but not accrued as expendrture. All eXpendrtu￿ ts inclusive of Irrecoverab￿ VAT. 2.5 Tangible fixed assets and depre¢lation Tangible fixed assets are initialty reccgnised at CC6t. After re¢ognitK)n. under the c05t model. tsngible fixed assets are measured at cost less accumuLated deprecwtk)n and any accumuLaled Imp81mienl losses. All costs incurred to bring a tangib￿ fixed assét into rts Intended hfvDrf(ing widitKsn should be induded in the measurement of cost. DeP￿￿tIOn 15 eharged so as to alkxate Ihe c05t of tsngible fixed assets less their resKlual value over their estimated useful lives. using the strawjht-line methcJ. Depr￿latIOn is prowded on the following bases". Freehokl propety (excluding landl Property fixtures and ffttings Office equipment CompLrter equipment - stra￿h1 line over 50 years stra￿bI line over 10 years 25°A slraight line 25¥0 slrwght line 2.6 Investments Fixed asset investments are a form of firbancral Inst￿Ment and are inrtplty recognised at th￿r transact st and subsequentty measured at fair value at the BaLonce Sheet dale, Un￿$$ the value cannol be measured relkqbly in whKh case rt is measured at cost W impaiment. Investment gains and losses, whether realised or Un￿all$ed. are combined and presented as 'Gainsl{Lossesl on investments, in the SL*ement of Financ￿1 Aetmties. 2.7 Investments Propertlgs Investment propefrtes are measured at fair value at each reKK)rting date with changes In fair value recognised in "net gains I Ilossesl on investment properties- in Ihe Statement of Financ￿1 Aetivf(ie$. 12

INFLAMMATORY NEUROPATHIES UK Notes to the Financial Statements (continuèd) for the year ended 31st March 2026 2.8 Debtors Trade and other debtors are rewgnised at the settlement amount after any trade discount offered. Prepayments are valued al the amount prepaid net of any trade discounts due. 2.9 Cash at bank and In hand Cash al bank and in hand includes cash and $hort-term highly I￿Uld investments wfth a short maturity of three months or1è5s from the date of acquisition or opening of the deposit or similar account. 2.10 Lbabllllles ¥nd provlslons Liabilities are recognised when there Is an obligation al the Balance Sheet dale as a result of a past event, il is probable that a transfer of economic benefit will be requiied in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised al thè amount Ihat the Chafily anlicipales il will pay lo settle the debt or the amount it has received as advanced payments for thè good8 or sorvices il musl provide. Provisions are measured al the best estimate of the amounts required lo settle the obligation. Where tho effect of the lime value of money Is material, the provision 18 based on the present value of Iho$fj amounts. discounted at the pre-tax discount rale that reflects the risks specific lo the liability. The unwinding of Ihe discount is recognised in the Slalemenl ol Financial Activities as a financè cost. 2.11 Flnanclal Instrumonts The Charity only has financial assets and financial liabilities of a kind that qualfy as basic financial inslrumants. Basic linancial in51rumenls are inrtially recognised al transaction value and subsequent measuied al their settlgmenl value with the èxception ol bank loans which are subsequently measured at amortised w&1 using the effectivo interest melh(>a. 2.12 Pen8lons The Charity operat88 8 defined contribution pengion scheme and the pansion ¢harg• iepresenls the amounts payable by the Charity lo tha fund In respect ol the year. 2.13 Fund Accountlng General funds are unreslrieled funds which are available for use at the discretion of the Tru$lee8 in furtherance of the general objoclives of the Charity and which have not been designated for other puiposes. Designated funds comprise unreslricled funds that have been set aside by the Tru$lees for particular purposes. Thg aim and use of each designated fund is sel out in the notes lo the financial statemonls. Investment income, gains and losses are allocated lo the appropriate fund. Analysls of Incom• 2026 026 Unre8trlcted Rostrlctgd Endowmènt Funds Funds Funds 2025 Total Total Donatlons and Legacles Donations Grants Legacies 132.9 5,000 352,379 490,369 132,990 5,000 352,379 490,￿9 157.980 16,860 174,840 Fundraising Fundraising 1,333 1,333 1,333 1,333 3,843 3,843 Other Tradlng A¢tlvltles Res¢ar¢h Sales of cards and 9oods 2,WO 2.000 3.004 5.004 3.004 S,004 3,979 Invoslrngnt Income Interest income 13,792 13.792 13,792 13,792 13,450 13.450 510,498 510.498 196,112 Page 13

INFLAMMATORY NEUROPATHIES UK Notes to the Financial Statements (continued) for the year ended 31st March 2026 4. Analysls of Exp•nditurn by activities 2026 2025 A¢ti¥lties Undertaken Directly Grant Aclivit•es Support Costs Totsl Total Research and raising awaoness 36.814 49.941 195.752 282,S07 196.%2 Raislng Aw•r•n688 16.884 19.930 2026 Total 16.884 19.930 36.814 2025 Total 16.503 Anatysls of Dlrnct costs Advertising & marketing costs Project Costs 16.503 Raising Awarenes• 129,456 3.708 2026 Total 129,456 3,708 2025 Total 99,386 1,453 9.270 13,774 329 12231 Analy818 of support costs Staff cosls Staff training and wiferences Staff ageney costs Depreciation Rrfruitmenl Water rales Repairs Miscellaneous Licenses and Sub￿ript￿)n# Rent arKI servKe charge Tebphone and Computer Print and postage Insurance Equipment hire Travel Legal and prOfeSs￿n81 Bank charges Accountancy Office eosls c￿anIng and waste di8poso1 Govemance costs . trustées expenses rembursed 117,7111 345 181 8.880 2.208 8,194 3.624 S.257 7,329 2,121 12.402 8,178 13,405 128 3.540 2,622 1,820 65 195.752 117,711 345 181 8.880 2.208 8.194 3,624 5,2S7 7,329 2,121 12,402 8.178 13,405 128 3.540 2.622 1,820 65 195.752 831 4,131 624 3,710 5,445 1.925 11.885 3.186 4,270 187 2.826 2,803 2,109 1,340 Grants to Grants to Institutlons Indlvidual 25.OC(I 24.941 25.oc 24.941 2026 Total 49.941 49.941 2025 Total 10,412 10.412 Anatyils of Grants Grants avrarded Page 14

INFLAMMATORY NEUROPATHIES UK Notes to the Financial Statements (continued) for the year ended 31st March 2026 5. Staff Costs 2026 202S Wages and salaries Scial security costs penS￿n costs 121.355 5,389 2.712 129456 92,S17 4,429 2,440 Average number of empbyees dumg the >tar Management and administration 2026 2025 The number of emplo￿ ¥vthose empw beneffts (èxcluding empbyr pension e41$1$) exceeded £60.000 was I12025- 01 Total rgmuneratDn including nat￿nal insurance and penS￿n conlribut*)ns in respect to key managemènt personnel totalK￿ £71,87012025- £61.142 6. Tru8t•os r•mun•ratlon and •xwnses During the yoar, no Trustees retsived any remunerat￿1 or benefits I2025- £nill. During the year ended 31 Mar¢h 2026, tsxpensese totalling £65 were reimbursed or directy lo the Truslee812025- £1.3401 in respect lo travel costs for meetings. 7. Tanglblfj flx•d aM•ts Property Frn•hold Fixtures & Property Fittings Office Computor Equlpment Equipmont Total Cost Brought frtvd at 1st Apr 2025 Additions Transfers lo Inve$lment property Carried at 31st Mar2026 278,350 77,471 2,305 1,315 367,514 1,315 1278,3501 1278.3501 77.471 9,388 3.620 90,479 Depreclatlon Brought flwd al 1st Apr 2025 Charge for the year Transfers to investment prcpety Carried f￿d at 31st Mar 2026 26.079 126.079} 47,723 7,747 83.994 (17.7111 621 55.470 9.388 1,425 66,283 Net book value At 31 sl Mar 2026 At 31 sl Mar 2025 252 271 283 520 Page 15

INFLAMMATORY NEUROPATHIES UK Notes to the Financial Statements (continued) for the year ended 31st March 2026 Fixed asset investments Investment Unlisted Property Investments Cost or valu*ion Brought flwd al 1st Apr 2025 AddrtKJns Revaluations 116,579 278,350 21.650 5,093 CarrEd flwd at 31st Mar 2026 300,000 121,672 Net book value At 31 sl Mar 2026 300 000 121672 At 31st Mar 2025 116579 9. Debtors 2026 Total 2025 Total Other debtors Prepayments and accrued income 13 7,278 21,097 7,291 21,983 10. Creditor5: falling due within one year 2026 Total 2025 Total Trade credi(ors Other creditors Other lax8tion and secur Accruals and deferred income 4,160 705 4.546 26.432 3,047 509 2,950 3.436 35.843 9.942 Page 16

INFLAMMATORY NEUROPATHIES UK Notes to the Financial Statements (continued) for the year ended 31st March 2026 11. Funds 2026 At1Apr 2025 Incomlng Outgoing Resourcos R•sources Trdnsfw5 At 31 Mar 2026 Unrnstrictod funds Deswna16d lunds Propety fund 252,271 21,650 26.079 300,000 General fund 740.308 515,591 1286.7601 126,0791 943,(EO Total fuTrd• 992 579 537 241 286 760 1243 C60 The fvThJs are conslrtuled as folh>4rt: DeS￿nated funds".- Pr¢werty fund . thLS fund reflects the market value of the propety hdd by Infiammatory Neuropathies UK. 2026 Unrnslrfcted Funds 2025 T¢)tal Total Tangible f￿ad assets Fixed asset unlisted investments Fixed asset inveslmenl property Current assets Cfedrtors 24.196 121,672 300.C 833,035 135,8431 24.196 121,672 3(Kl,000 833.035 {35.8431 283.520 116,579 602,422 19,9421 1.243,1%0 1.243.060 992,579 12. Penslon comfflltm•nts The Charty operates a defined contribLrtK•ns PenS￿n scheme. The assets of the scheme are hekl separalety from those of the Charrty in an independenlty administered fund. The pension ¢osl charge mpresenls contributions payable by Ihe Charty to the fund and amounted to £2,71212025- £2.440}. Contribulions t¢)tslling £705 {2025- £5091 ere Payab￿ to the fuThJ at the balance sheet date arKI are included in credrtors. 13. R•l•ted party tra￿￿CtiO1v& Other than disclosed ab)ve ry elSehe￿ in these fingn¢k41 ststemenls, there were no other transactions wlh related parties requiring dI￿￿SUre. 14. Lessoe Commbtments under operntlng leas At 31 sl March 2026 the totsl future mininum ￿ase pawnen15 under non<an¢dlable operating lèases are as fo11ch￿.. 2026 2025 Other operab.ng leases wh￿h exptye.. No later that 1 year Later than 1 year and not bater than 5 years Later than 5 years 18,112 21,960 9.472 17.032 P￿e 17

INFLAMMATORY NEUROPATHIES UK Notes to the Financial Statements (continued) for the year ended 31st March 2026 15. Lessor Commitments under opgrating leases Al 31st Ma￿h 2026 the total fLrture minwnum ￿ase Itt￿p1S under non<ancelL4ble OFerating leases are as follows.. 2026 2025 Other operating leases Wh￿ expire.. No kter that 1 year Later than 1 year arKI Thjt later than 5 ye8lS Later than 5 years 22.5(K) 43.125 Page 18

Pages 20 10 22 8lso lom7part ollhese finartial statemgrts 8nd s￿W Ihe cwparnlrrfe 2025 fwurgs. Page 19

INFLAMMATORY NEUROPATHIES UK Notes to the Financial Statements Icontinued) for the year ended 31st March 2026 16. Fund comparatlves Statement of FinancialAdivides 2025 Unrnstslcted funds 2025 Total Ineome In)m.' Donatws andkgacAes FundTrwr Other Trading &tMties Investments 174.840 3,843 3.979 13,450 774,840 3,843 3,979 13,450 Total Incomlng rescwrces 196. 7 12 796, 7 12 Expenditurn on.. Raising Funds Chaitabk Acbvities 6.266 196,962 6,266 196.962 Total gxpgnded rnsources 203,228 203,228 Net /(losss) ¢>n investments 4.906 4.906 Net (expenditurn) /lncome Net movement In funds (2,210) (2.210) (2,210) (2,210) Reconclllatlon of funds." Total funds fO￿ard 994. 789 994, 789 Total funds canied fonvanl 992 579 992 579 Analysis of income Unrestricted Funds 2025 Total Donations and Legacles D￿ationS L8gacs 157.980 76,860 174, 840 15T,980 16,860 174,840 Fundrai￿ng FUndth￿lng 3,843 3, 843 3,843 3.843 Other Trading Activities Sales of ca￿S and gcojs 3.979 3.979 3.979 3.979 Investment Incolive Investment income 13,4&) 13.450 13.450 13.450 196 112 196 112 Paje 20

INFLAMMATORY NEUROPATHIES UK Notes to the Financial Ststements (continued) for the year ended 31st March 2026 16. Fund comparatlves (coneinued) Analysls of Expendlturn by adivibos Activities Undertakw¥ Directly Grnnt Activitios Support Costs 2025 Total Research 8nd raisNw awareness I6,￿3 10.412 170,047 196,962 Ralslng Awargness 76,503 2025 Total 16.503 16,503 Analysis olDlrgCt costs Newsl8tler costs Ralslng 2025 Total 99,386 1,453 13. 774 329 (223) 786 9.270 837 4. 131 624 3, 710 5,445 1,925 11,885 3, 186 4,270 187 2,826 2,803 2, 109 1,340 An•tysls of support costs Staff costs Staff lrnining 8nd ¢onlerwKes Depre¢￿tion Recniitment Waler ral8S Repai Staff t7gency costs Miscellaneous Lic8ns&s 8nd subscnplions Renl and seryice charge Telephone and compuler Print andp)st8ge Insur8nc8 Equipment hire Tr8vel Legal atKI ptDfessional 88nk charges Independent ex8minlA)n OffKe costs Cleaning and waste thsposal Govemance cosls- Irustw Iravd rginbursed 99,386 1,453 13. T74 329 (223) T86 9.270 837 4,131 624 3,710 5,445 1,925 11,885 3, 186 4,270 187 2.826 2,803 2.109 1,340 170,047 Grants to Grants to Institutions Indlvldu8ls 70.412 2025 Total 10,472 Analysls ol Grants Grants aw8rded Page 21

INFLAMMATORY NEUROPATHIES UK Notes lo the Financial Statements (continued) for the year ended 31st March 2026 16. Fund eomparatlves (contlnued) Funds 2025 AtIApr 2024 Incomlng Outgolng Resources Resources Transfers At31 Mar 2025 Unrnstrlcted funds Deswnaled funds Propety lund General fund 257,838 (5,567) 5,567 252,271 736.957 201.018 (203.228) 740,308 Total Unr6strl¢ted Funds 994. 789 201,018 203,228 992,579 The lunds are constiluled as lollows.. Des￿n&t&d funds... Propety fund- this fund refl8cls the net book value of lh8 prop8ty held by GAIN. 2025 Total UnTrstrlct8d Funds Tangible r￿ed assets Fixed asset invgstmenl$ Current assets c￿dI10 283.520 176,579 602,422 (9,942) 283,520 176,579 602,422 (9,942) 992 579 992 579 Page 22